Results 81 to 90 of about 983,540 (218)

SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines

Human Vaccines & Immunotherapeutics, 2023
Certain aspects of the immunogenicity and effectiveness of the messenger ribonucleic acid (mRNA) vaccines (mRNA-1273 and BNT162b2) developed in response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic are still ...
Thomas E. Hickey, Troy J. Kemp, Jimmie Bullock, Aaron Bouk, Jordan Metz, Abigail Neish, James Cherry, Douglas R. Lowy, Ligia A. Pinto   +8 more
doaj   +1 more source

Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study

British medical journal, 2021
Objective To estimate the effectiveness of mRNA covid-19 vaccines against symptomatic infection and severe outcomes (hospital admission or death). Design Test negative design study.
Hannah Chung, Siyi He, S. Nasreen, M. Sundaram, S. Buchan, Sarah E. Wilson, Branson Chen, A. Calzavara, D. Fell, P. Austin, K. Wilson, K. L. Schwartz, K. Brown, J. Gubbay, N. Basta, S. Mahmud, C. Righolt, L. Svenson, S. MacDonald, N. Janjua, M. Tadrous, J. Kwong   +21 more
semanticscholar   +1 more source

Relationship between immune response to SARS-CoV2 vaccines and development of breakthrough infection in solid organ transplant recipients: the CONTRAST cohort [PDF]

, 2023
Background: SARS-CoV-2 vaccination in solid organ transplant (SOT) is associated with poorer antibody response (AbR) compared to non-SOT recipients. However, its impact on the risk of breakthrough infection (BI) should yet be assessed.
Bonazzetti, Cecilia, Borgese, Laura, Busutti, Marco, Caroccia, Natascia, Comai, Giorgia, Fanì, Francesca, Fornaro, Giacomo, Gamberini, Chiara, Giannella, Maddalena, Gibertoni, Dino, Lazzarotto, Tiziana, Miani, Beatrice, Morelli, Maria Cristina, Pascale, Renato, Pasquini, Zeno, Potena, Luciano, Rinaldi, Matteo, Salvaterra, Elena, Scudeller, Luigia, Tamé, Mariarosa, Tazza, Beatrice, Viale, Pierluigi   +21 more
core   +1 more source

Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults

Human Vaccines & Immunotherapeutics, 2023
This interim analysis of an ongoing phase 1 randomized clinical trial evaluated the safety, reactogenicity, and immunogenicity of mRNA-1283, a next-generation SARS-CoV-2 messenger RNA (mRNA)-based vaccine encoding two segments of the spike protein (i.e ...
Patrick Yassini, Mark Hutchens, Yamuna D. Paila, Lorraine Schoch, Anne Aunins, Uma Siangphoe, Robert Paris   +6 more
doaj   +1 more source

Sudden Sensorineural Hearing Loss Following Immunization With BNT162b2 or mRNA-1273:A Danish Population-Based Cohort Study [PDF]

, 2023
Objective: To compare the occurrence of sudden sensorineural hearing loss following immunization with BNT162b2 (Comirnaty®; Pfizer BioNTech) or mRNA-1273 (Spikevax®; Moderna) to the occurrence among unvaccinated individuals.
Cleary, Brian, Damkier, Per, Hallas, Jesper, Jensen, Peter B., Ladebo, Louise, Lund, Lars Christian, Schmidt, Jesper H.   +6 more
core   +1 more source

Comparing the human milk antibody response after vaccination with four COVID-19 vaccines:A prospective, longitudinal cohort study in the Netherlands [PDF]

, 2022
Background: Vaccination of lactating women against COVID-19 may protect not only themselves but also their breastfed infant through human milk. Therefore, it is important to gain insight into the human milk antibody response after immunization with the ...
Bakker, S., Bouhuijs, J.H., Coenen, E.R.M., de Groot, C.J.M., Harinck, J.E., Juncker, H.G., Korosi, A., Mulleners, S.J., Oomen, M., Pajkrt, D., Rood, R.D., Ruhé, E.J.M., van Doesburg, M., van Gils, M.J., van Goudoever, J.B., van Keulen, B.J.   +15 more
core   +1 more source

Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study

British medical journal, 2021
Objectives To evaluate the effectiveness of the mRNA-1273 vaccine against SARS-CoV-2 variants and assess its effectiveness against the delta variant by time since vaccination. Design Test negative case-control study.
K. Bruxvoort, L. Sy, L. Qian, B. Ackerson, Yi Luo, Gina S. Lee, Yun Tian, A. Florea, Michael Aragones, J. Tubert, H. Takhar, J. Ku, Y. Paila, C. Talarico, H. Tseng   +14 more
semanticscholar   +1 more source

Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients

American Journal of Transplantation, 2021
According to preliminary data, seroconversion after mRNA SARS‐CoV‐2 vaccination might be unsatisfactory in Kidney Transplant Recipients (KTRs). However, it is unknown if seronegative patients develop at least a cellular response that could offer a ...
D. Cucchiari, Natalia Egri, M. Bodro, Sabina Herrera, J. Del Risco-Zevallos, J. Casals-Urquiza, F. Cofan, A. Moreno, J. Rovira, E. Bañon-maneus, M. Ramirez-Bajo, P. Ventura-Aguiar, Anna Pérez-Olmos, Marta Garcia‐Pascual, M. Pascal, A. Vilella, A. Trilla, J. Ríos, E. Palou, M. Juan, Beatriu Bayés, F. Diekmann   +21 more
semanticscholar   +1 more source

Development of SARS-CoV-2 specific IgG and IgA antibodies in serum and milk with different SARS-COV-2 vaccines in lactating women [PDF]

, 2023
Background: Our main objective was to determine the evolution of IgG and IgA antibodies directed against SARS-CoV-2 protein S in the blood of lactating women and in breast milk.
Cabero Pérez, María Jesús, Cuesta González, Rocío, Gómez Acebo, Inés, Irure Ventura, Juan, Lechosa Muñiz, Carolina, Llorca Díaz, Francisco Javier, López Hoyos, Marcos, Mendez-Legaza, Jose Manuel, Paz Zulueta, María   +8 more
core   +1 more source

Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)

International Journal of Infectious Diseases
Objectives: To assess the safety and immunogenicity of a fourth vaccination (second booster) in individuals aged ≥75 years. Methods: Participants were randomized to BNT162b2 (Comirnaty, 30 µg) or messenger RNA (mRNA)-1273 (Spikevax, 100 µg).
Jannik Stemler, Lusine Yeghiazaryan, Christoph Stephan, Kristin Greve-Isdahl Mohn, Antonio-José Carcas-Sansuan, Esperanza Romero Rodriguez, José Moltó, Itziar Vergara Mitxeltorena, Tobias Welte, Birutė Zablockienė, Murat Akova, Ullrich Bethe, Sarah Heringer, Jon Salmanton-García, Julia Jeck, Lea Tischmann, Marouan Zarrouk, Arnd Cüppers, Lena M. Biehl, Jan Grothe, Sibylle C. Mellinghoff, Julia A. Nacov, Julia M. Neuhann, Rosanne Sprute, Jesús Frías-Iniesta, Riya Negi, Colette Gaillard, Gurvin Saini, Alejandro García León, Patrick W.G. Mallon, Christine Lammens, An Hotterbeekx, Katherine Loens, Surbhi Malhotra-Kumar, Herman Goossens, Samir Kumar-Singh, Franz König, Martin Posch, Philipp Koehler, Oliver A. Cornely   +39 more
doaj   +1 more source